CervoMed Inc. (CRVO)

NCM – Real Time Price. Currency in USD

3.08

-0.01 (-0.32%)

Market open: Aug 12, 2026, 11:37 AM EDT

3.12

+0.03 (0.97%)

Previous after-hours: Aug 11, 2026, 7:57 PM EDT

10.08.2026

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingdom's Innovative Licensing and Access Pathway (ILAP) for development in DLB New analyses presented at the Alzheimer's Association International Conference (AAIC) 2026 reinforce neflamapimod's treatment effect in pure DLB and support 50 mg TID dose for planned Phase 3 trial Initial, 12-week biomarker data from Phase 2a clinical trial in nonfluent variant primary progressive aphasia (nfvPPA) to be presented at the 15 th International Conference on Frontotemporal Dementia (ISFTD) in October 2026; full 12-week and initial, 24-week biomarker data to be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in November 2026 Completed two equity financings in June 2026 for aggregate gross proceeds of approximately $20.5 million, extending cash runway through the third quarter of 2027 BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today reported financial results for the second quarter ended June 30, 2026, and provided corporate updates. “The second quarter was marked by meaningful progress across both our business and pipeline.

05.08.2026

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, being held in Boston, MA, on Tuesday, August 11, 2026. During the fireside chat, management will share recent progress in neflamapimod's clinical development program.

04.08.2026

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines

Videos

No Data

There is no data to display

Press releases

10.08.2026

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

05.08.2026

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

04.08.2026

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines

CervoMed Inc. (CRVO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

CervoMed Inc. (CRVO)

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

Videos

No Data

Press releases

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

Videos

No Data

Press releases

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

Search stocks

CervoMed Inc. (CRVO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

CervoMed Inc. (CRVO)

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

Videos

No Data

Press releases

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

Videos

No Data

Press releases

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)